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ABSTRACT 
Introduction: Arteriovenous fistula or graft (AVF/AVG) use is widely considered contraindicated 
for continuous renal replacement therapy (CRRT), yet insertion of hemodialysis (HD) catheters 
can carry high complication risk in critically ill end-stage renal disease (ESRD) patients.   
Methods: Single-center analysis of 48 consecutive hospitalized ESRD patients on maintenance 
HD who underwent CRRT using AVF/AVG in 2012-2013. Primary outcome was access-related 
complications.  
Findings: Mean age was 60 years, 48% were male, and 88% required vasopressor support. 
Median duration of AVF/AVG use for CRRT was 4 days (range 1-34). Ten (21%) patients had 
access complications (5 bleeding, 5 infiltration, 1 thrombosis); 5 (10.4%) required catheter 
placement.  Overall 31 (65%) patients survived to hospital discharge and AVF/AVG access was 
functional at the time of discharge in 29 (94%) patients.  
Discussion: In our experience, use of AVF/AVG for CRRT can be performed with a low serious 
complication rate and low risk of access loss, potentially avoiding catheter-related 
complications. 
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INTRODUCTION 
Patients with end-stage renal disease (ESRD) undergoing maintenance hemodialysis (HD) are 
hospitalized an average of 1.7 times per patient per year.
1
  During hospitalization, ESRD 
patients are typically managed using a similar prescription to their outpatient regimen.  An 
exception, however, is in critically ill patients admitted to the intensive care unit (ICU) who may 
require continuous renal replacement therapy (CRRT). In these situations, dialysis catheters are 
considered the preferred access for CRRT and the use of an arteriovenous fistula (AVF) or 
arteriovenous graft (AVG) is widely considered contraindicated due to concerns about patient 
safety and access longevity.
2-4
 
As such, most centers place temporary dialysis catheters in ESRD patients who require CRRT, 
even in the presence of a functional AVF or AVG. Yet insertion of catheters may be complicated 
due to a significant history of prior vascular catheterizations in many ESRD patients, and 
exposes patients to the risk for mechanical complications.
5
 Presence of an indwelling dialysis 
catheter also increases the risk for infectious complications in this high-risk population.
6, 7
 
In our tertiary care center, we routinely use functional AVF/AVG for access when CRRT is 
prescribed in ESRD patients. Here we describe our experience over a two year period, focusing 
on safety and efficacy outcomes.  
 
METHODS 
Subjects and Setting 
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This single-center, retrospective study was performed at the University of Michigan Health 
System (UMHS) in Ann Arbor, Michigan.  Inclusion criteria consisted of: (1) age ≥ 18 years; (2) 
diagnosis of ESRD on maintenance HD; (3) functional AVF or AVG as their dialysis access; and (4) 
underwent CRRT during the two-year period of 2012 through 2013. Patients were excluded if 
they were on maintenance peritoneal dialysis (PD) or if they were catheter-dependent prior to 
initiation of CRRT. The protocol was approved by the University of Michigan Institutional 
Review Board with a waiver for informed consent. 
 
CRRT Vascular Access Protocol 
The decision to utilize an AVF/AVG for CRRT access (versus placing a new dialysis catheter) is at 
the discretion of the nephrology dialysis consult team.  General considerations include 
expected duration of CRRT, patient cognitive status, presence of coagulopathy, and baseline 
functionality of the access.  CRRT is performed at UMHS using a regional citrate anticoagulation 
protocol in hemodiafiltration (CVVHDF) mode, with blood flow rates of 150-200 ml/min and 
target prescribed effluent dose of 25-30 ml/kg/hr. 
CRRT is performed on a cooperative basis between the dialysis team and ICU nursing.  In the 
ICU, nursing staff with at least one year of ICU experience are eligible to undergo CRRT-specific 
training.  This consists of eight hours of didactic class with a hands-on component, followed by 
12 hours of bedside orientation with direct supervision and checklist requirement. Training 
specific to AVF/AVG use encompasses anatomical description of flow patterns, dressing 
integrity including use of arm boards for stability as needed, and needle discontinuation in the 
case of infiltration or other complication. 
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CRRT access needles (steel, 15 gauge) are placed and exchanged by dialysis nursing staff 
following similar procedures to standard intermittent HD. While dialysis nurses take primary 
responsibility for needle placement/adjustment/removal, ICU nurses are trained to identify 
complications (such as infiltration) and to remove needles in emergent situations. The access is 
to be available for direct visualization at all times, and integrity of the access is checked on an 
hourly basis by the bedside ICU nurse and examined daily by a dialysis nurse. By policy, access 
needles are routinely replaced at least every 96 hours or after any down time exceeding 12 
consecutive hours. For procedures with expected short duration, CRRT needles are kept in 
place and capped after disconnection from the CRRT machine. Once CRRT is initiated via 
AVF/AVG, the dialysis nurse hands off care to the bedside ICU nurse, but remains available for 
troubleshooting.  
 
Data Collection 
Data were collected through review of the medical chart, nursing notes, as well as incident 
reports.  In addition to basic demographics, information on comorbidities and primary diagnosis 
for ICU admission was collected.  Pre-existing access problems, defined as prolonged bleeding, 
any access intervention within the past year (e.g. fistulogram with angioplasty), or aneurysm, 
were also recorded.  Additional data included length of ICU stay and duration of vasopressor 
and CRRT requirements.  We collected data on complications that developed during use of the 
CRRT access, defined as bleeding around needles, infiltration/hematoma, or thrombosis.  The 
number of patients requiring catheter placement, viability of original vascular access at 
discharge, and patient survival to hospital discharge were also captured. 
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Outcome Measures 
The primary outcomes were the type of dialysis access at the time of hospital discharge, as well 
as the rate of complications of using AVF/AVG for CRRT access.  Secondary outcomes included 
in-hospital mortality and complications associated with the placement of new dialysis access.  
 
Statistical Analyses 
For this descriptive study, categorical variables were presented as percentages, while 
continuous variables were presented as means with standard deviations when normally 
distributed, or as medians with interquartile range when non-normally distributed. 
 
RESULTS 
Subjects 
There were a total of 95 ESRD patients who required CRRT during the study period.  Forty seven 
(49%) patients were excluded from further analysis because they did not undergo CRRT using 
an AVF or AVG (Figure 1).  A clinical decision was made to not use the AVF/AVG in three of 
these patients (1 dysfunctional, 1 aneurysmal, 1 “save for intermittent HD”).  The final cohort 
consisted of 48 patients.  A summary of patient characteristics is presented in Table 1.  
Approximately half of the patients were male, with mean age 59.6 years and a mean dialysis 
vintage 66.3 months. The majority (37/48, 77%) had an AVF as their dialysis access, and 25% of 
all patients had documented pre-existing access problems. Most patients (42/48, 87.5%) 
required vasopressors. The majority of the patients were either sedated (64.6%) or awake and 
Page 6 of 18Hemodialysis International
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
7 
 
following commands (27.1%) when treatment was started; four patients were confused and not 
sedated at the time of the CRRT initiation. The median duration of CRRT was four days, with a 
range from one to 34 days (Table 2). 
 
Vascular Access Complications 
Ten patients (20.8%) had a CRRT-related access complication (Table 3), and eight of these 
patients had an AVF as their dialysis access. Five of these 10 patients (10.4% of the total cohort) 
required catheter placement, four of whom had pre-existing access issues documented before 
admission. Of patients who required catheter insertion, one required blood products for line 
placement and one subsequently had a catheter-related bloodstream infection.  
 
Patient Outcomes 
At discharge, the original dialysis access was viable in 45 of the initial 48 patients (93.8%) and in 
29 of the 31 patients (93.5%) who survived to hospital discharge (Table 3). Seven of the ten 
patients with access complications survived, and five had their original access usable at 
discharge. 
 
Following discharge, five of the 31 surviving patients were documented to have interventions 
on their access within the subsequent six month period. All five accesses were salvaged and 
usable post-intervention.  
 
DISCUSSION 
Page 7 of 18 Hemodialysis International
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
8 
 
Use of AVF/AVG for CRRT is widely considered to be contraindicated due to concerns for 
patients’ safety and access longevity,
2
 yet there are no studies to describe the potential harm 
resulting from this approach or how it compares to routine use of temporary dialysis catheters. 
At the University of Michigan, we have employed a protocol to routinely utilize AVF/AVG access 
in ESRD patients requiring CRRT.  During our study period of two years, we did not observe any 
adverse outcomes that directly affected patient hospital mortality. While access-related 
complications were not infrequent, these were generally minor and only 10% required dialysis 
catheter placement.  The vast majority of patients (94%) had a viable vascular access at 
discharge.  These findings suggest that AVF/AVG can be used safely and effectively for CRRT 
care in patients with ESRD, although the long-term safety of this practice requires further 
evaluation. 
 
Vascular access infiltration or hematoma were the most common adverse effects observed. 
Indeed, these are relatively common complications even in the general ESRD population; Lee et 
al. reported an annual major (requiring temporary catheter placement) fistula infiltration rate 
of 5.2% in a ohort of non-hospitalized ESRD patients.
8
 In our population of critically ill patients 
with hypotension and pressor requirements, it would be reasonable to expect a higher rate of 
complications. Indeed, both intradialytic hypotension and lower pre-dialysis blood pressure 
have been identified as independent risk factors for AVF thrombosis.
9
 Among the five patients 
who required dialysis catheter placement for access complications, two had their AVF/AVG in 
use again by the time of hospital discharge.  Of the three patients who lost their access by the 
time of discharge, only in one patient was this thought to be potentially related to the use of 
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the access for CRRT. One of the other two patients had experienced multiple recent thrombosis 
episodes prior to ICU admission (and actually already had a new AVF placed awaiting 
maturation), and the other patient had severe central venous stenosis complicated by 
thrombosis following a pacemaker insertion during the hospitalization. Therefore, pre-existing 
access issues may be an important factor in risk stratifying which patients may be suitable 
candidates for use of AVF/AVG for CRRT. 
 
Use of dialysis catheters for CRRT is the current standard of care, but this may not be a benign 
procedure. First, there can be a significant delay in initiation of CRRT while awaiting 
coordination and placement of a new temporary catheter. Secondly, catheter placement in 
ESRD patients may be particularly challenging due to many patients having prior vascular 
cannulations, as underlined by the fact that approximately 80% of incident U.S. ESRD patients 
have a dialysis catheter as their first access.
1
 Although catheter insertion complication rates are 
not well-described in the ESRD population, studies in other populations support a cautious 
approach. D nys et al. described 34 cardiac transplant patients in which the internal jugular 
vein was not visualized, presumably due to occlusion or thrombosis from multiple prior 
cannulations for right heart catheterization procedures.
10
 Similarly, Mansfield et al. found prior 
catheterization to be a risk factor for failure of central venous catheter insertion.
11
 Mechanical 
complications are another risk that is associated with catheter insertion and they occur despite 
the use of dynamic “real-time” ultrasound guidance. Arterial puncture has been described at 
variable rates of 1.39% to 14% of insertions, potentially affected by operator experience.
10, 12, 13
 
Additionally, arterial cannulation with large-bore catheters continues to occur with, in many 
Page 9 of 18 Hemodialysis International
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
10 
 
cases, catastrophic outcomes.
5
 Lastly, dialysis catheters, both non-tunneled and tunneled, add 
significant risk for infectious morbidity and mortality.
2, 6, 7
 By using an existing AVF/AVG access, 
we were able to avoid temporary dialysis catheter placement (and any associated risks) in 90% 
of our ESRD patients requiring CRRT. 
 
One potential risk from using an AVF/AVG for CRRT is unrecognized extravasation due to needle 
dislodgement. Dislodgment of the arterial needle will invariably lead to a machine alarm for 
pressure differential or air entering the circuit.  However, the return pressure created by the 
relatively small lumen of the venous cannulation needle may be sufficient to prevent pressure 
alarms from being triggered even if the needle is dislodged. This risk also exists when an 
AVF/AVG is used for standard intermittent hemodialysis, and thus vascular access is required to 
be visible at all times. We employ the same policy to avoid this complication while using 
AVF/AVG for CRRT; the arm is always exposed and visible to the nurse. During our two year 
study period, there were no instances of unrecognized extravasation related to needle 
dislodgement. 
 
A critical aspect to the success of using AVF/AVG in our CRRT program is the cooperation 
between dialysis and critical care nursing.  To achieve appropriate buy-in from ICU nurses, who 
are generally not familiar or comfortable with dialysis vascular access, we maintain an ongoing 
focus on nursing CRRT education.  Understanding that this is a potentially high-risk practice, we 
promote a safety culture by encouraging routine reporting of all potential adverse events.  The 
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institutional CRRT committee, which includes nursing members from each ICU, reviews all 
CRRT-related safety incidents and disseminates informational updates as needed.  In addition, 
dialysis nurses provide support for any access-related issues. 
 
Our study has some limitations worth noting. First, as a retrospective study, we relied on 
adequate documentation to identify complications. It is possible that not all complications were 
appropriately recorded in the medical chart; however, we believe that all serious complications 
(i.e. affecting patient care, including need for catheter placement) were recorded, either in the 
medical notes or the patient safety reporting system. Second, very limited data about long-term 
consequences was available to us as many patients were not longitudinally followed in our 
center after hospital discharge. However, the primary outcome of the dialysis access at the time 
of discharge is accurately and completely documented on all the study subjects. Thirdly, 
because we routinely use AVF/AVG for CRRT whenever feasible, we did not have a comparison 
group of ESRD patients managed with the alternate strategy of dialysis catheter placement. 
Importantly, only one of our patients lost use of their vascular access potentially related to 
CRRT, and any benefit from using catheters would need to be weighed against the potential 
mechanical and infectious risks. 
 
In conclusion, our study suggests that the use of AVF/AVG for CRRT can be both safe and 
feasible, and this remains the first-line approach at our medical center. Further research to 
compare this approach to the routine use of catheters for CRRT in the ESRD population, and to 
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evaluate long-term access outcomes, should be conducted to better describe the comparative 
effects on patient outcome and safety. 
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Figure 1. Patient flow diagram. A description of the initial study cohort with application of 
exclusion criteria.   
HD: hemodialysis; PD: peritoneal dialysis; AKI: acute kidney injury; AVF: arteriovenous fistula; 
AVG: arteriovenous graft; CRRT: continuous renal replacement therapy 
 
      
 
  
  
Page 14 of 18Hemodialysis International
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
15 
 
Table 1: Characteristics of study patients at initiation of continuous renal replacement therapy. 
 
Variable Patient characteristic (n=48) 
Age in years, mean (SD) 59.6 (11.5), range 33-85 
Gender (male) 23 (47.9%) 
Dialysis Vintage in months, median 
[IQR] 
36.0 [17.5, 82.5], range  1-300 
Dialysis Access  
    AVF 
    AVG 
 
37 (77.1%) 
11 (22.9%) 
Pre-existing Access Problem: Any 
    Prolonged bleeding 
    Access intervention (within past year) 
    Aneurysm 
12 (25.0%) 
3 (6.3%) 
6 (12.5%) 
5 (10.4%) 
Diagnosis: 
    Septic shock 
    Cardiogenic shock 
    Hemorrhagic shock 
    Other 
 
17 (35.4%) 
23 (47.9%) 
3 (6.3%) 
5 (10.4%) 
Comorbidities 
    Diabetes mellitus 
    Hypertension 
    Congestive heart failure 
    Coronary artery disease 
    Peripheral veno-occlusive disease 
 
21 (43.8%) 
39 (81.3%) 
26 (54.2%) 
21 (43.8%) 
7 (14.6%) 
Mental Status 
    Awake and alert 
    Awake and confused 
    Sedated 
 
13 (27.1%) 
4 (8.3%) 
31 (64.6%) 
Requiring vasopressors 42 (87.5%) 
SD: standard deviation; IQR: interquartile range; AVF: arteriovenous fistula; AVG: arteriovenous 
graft;  
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Table 2: Treatment characteristics of study patients 
Variable Result (n=48) 
Duration of ICU stay in days, mean (SD) 10.6 (7.0) 
Duration of CRRT in days, median [IQR] 4 [3, 6], range 1-34 
Duration of CRRT using AVF in days, median 
[IQR] 
4 [3, 6], range 1-34 
ICU: intensive care unit; SD: standard deviation; CRRT: continuous renal replacement therapy; 
IQR: interquartile range; AVF: arteriovenous fistula 
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Table 3: Outcomes of study patients 
Variable Result (n=48) 
Documented CRRT-related access 
complication 
  Any 
  Bleeding around needles 
  Infiltration/hematoma 
  Thrombosis 
 
10 (20.8%) 
5 (10.4%) 
5 (10.4%) 
1 (2.1%) 
CRRT-related access complication, requiring 
line placement 
5 (10.4%) 
Access viable at discharge  
  All (n=48) 
  Among survivors (n=31) 
 
45 (93.8%) 
29 (93.5%) 
Survive to hospital discharge 31 (64.6%) 
CRRT: continuous renal replacement therapy 
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Figure 1. Patient flow diagram. A description of the initial study cohort with application of exclusion criteria.   
HD: hemodialysis; PD: peritoneal dialysis; AKI: acute kidney injury; AVF: arteriovenous fistula; AVG: 
arteriovenous graft; CRRT: continuous renal replacement therapy  
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